Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-06-02 M&A Activity
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals PLC
M&A Activity Classification · 90% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals PLC" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a mandatory disclosure required when a person or entity acquires or deals in relevant securities during a takeover offer, specifically disclosing their opening position or dealing activity. This type of filing relates directly to insider/major shareholder activity during a takeover scenario. While it involves director/insider dealings (DIRS) and major shareholding (MRQ), the specific context of the Takeover Code (Rule 8.3) points towards a specialized regulatory disclosure related to M&A activity. However, looking at the provided definitions, none perfectly match a 'Takeover Code Rule 8.3 Disclosure'. Let's re-evaluate the closest fits: 1. DIRS (Director's Dealing): This is a dealing disclosure, but specifically tied to a takeover context, not just routine insider trading. 2. MRQ (Major Shareholding Notification): This involves crossing ownership thresholds, which is related, but Form 8.3 is specific to the takeover process. 3. TAR (M&A Activity): This covers merger proposals or takeover bids. A Form 8.3 is a direct consequence and required filing during a takeover. 4. RNS (Regulatory Filings): This is the fallback. Given that Form 8.3 is a mandatory disclosure under the UK Takeover Code, it is fundamentally an announcement related to M&A activity (TAR). If TAR is interpreted narrowly as only the proposal/bid itself, then RNS might be safer. However, disclosures mandated by the Takeover Code are central to the M&A process. Since the document details ownership positions and dealings related to an ongoing takeover situation (implied by the reference to the Code), TAR (M&A Activity) is the most contextually accurate classification among the choices, as it deals with the mechanics of a takeover bid. If TAR is strictly for the initial bid announcement, then DIRS or MRQ might be considered, but this is a specific regulatory filing about interests during a takeover. Given the options, and the nature of the disclosure being directly tied to a takeover event, TAR is the best fit, although RNS is a strong secondary candidate if TAR is too narrow.
2023-06-02 English
Recommended Cash Offer: Dechra Pharmaceuticals PLC
M&A Activity Classification · 98% confidence The document is an official announcement dated June 2, 2023, originating from RNS (Regulatory News Service), indicated by the 'RNS Number' and the standard disclaimer language ('NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION...'). The content explicitly details a 'RECOMMENDED CASH ACQUISITION' of Dechra Pharmaceuticals PLC by Freya Bidco Limited, structured as a 'scheme of arrangement under Part 26 of the Companies Act 2006'. This subject matter—a takeover bid, scheme of arrangement, and recommendation by the board—falls directly under the category of M&A Activity (Takeover/Merger). The definition for M&A Activity is 'Announcements and documents related to merger proposals or takeover bids' (Code: TAR). Although it is an RNS announcement, the specific subject matter is a takeover, making TAR the most precise classification over the general RNS fallback.
2023-06-02 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header and contains a notification to the market regarding the 'Total Voting Rights' of the company as of the announcement date (31 May 2023). It explicitly states the total number of issued shares with voting rights (113,884,141) and references compliance with DTR 5.6.1R (Disclosure and Transparency Rules). This type of mandatory, short regulatory update, often distributed via RNS, fits best under the general 'Regulatory Filings' category, as there is no more specific code for 'Total Voting Rights' notification, and it is not a report itself (ruling 2 does not apply as it's not announcing another report).
2023-05-31 English
Form 8.3 - Dechra Pharmaceuticals plc
Regulatory Filings Classification · 95% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a Public Opening Position Disclosure or Dealing Disclosure made by a person holding 1% or more interest in relevant securities during a takeover situation. This type of disclosure relates specifically to insider/major shareholder dealings during a takeover bid, which falls under the scope of transactions involving securities and regulatory disclosure related to corporate control events. While it involves dealings, the specific context of a Takeover Code disclosure (Form 8.3) is not explicitly covered by DIRS (Director's Dealing) or POS (Transaction in Own Shares). However, it is a mandatory regulatory filing related to a takeover scenario. Given the options, this is a highly specific regulatory disclosure. Since it details holdings and dealings related to a potential takeover, it is most closely related to insider/major shareholder activity, but the structure strongly suggests a mandatory regulatory filing related to corporate control. In the absence of a specific 'Takeover Disclosure' code, and noting that it is a mandatory filing concerning share interests during a bid, it fits best under the general regulatory filing category (RNS) or potentially DIRS if interpreted broadly as insider dealing, but RNS is the safer fallback for specific regulatory forms not listed. Upon review, Form 8.3 is a specific disclosure required under the UK Takeover Code. Since there is no specific code for Takeover Disclosures, and it is a mandatory regulatory filing, RNS (Regulatory Filings) is the appropriate fallback category.
2023-05-26 English
Form 8.3 - Dechra Pharmaceuticals plc
Director's Dealing Classification · 95% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a Public Opening Position Disclosure/Dealing Disclosure made by a person holding 1% or more interest in relevant securities during a takeover situation. This type of filing relates to insider transactions or significant ownership changes during a takeover bid, which falls under the scope of director/insider dealings or major shareholding notifications, but the specific context of a Takeover Code disclosure points towards insider activity related to a specific corporate action (takeover). Among the provided codes, 'DIRS' (Director's Dealing) is the closest fit for reporting personal share transactions by executives/insiders, even though this is specifically a Takeover Code disclosure (Form 8.3). Since it details ownership and dealings of a person with interests in securities during a potential takeover, it is fundamentally an insider transaction report. It is not a general regulatory filing (RNS) because it is highly specific to insider dealing rules during a bid. It is not a Major Shareholding Notification (MRQ) as MRQ typically refers to crossing standard ownership thresholds outside of a formal takeover context, whereas Form 8.3 is mandatory during a Rule 32/37/38 event (takeover). Therefore, DIRS is the most appropriate classification for insider transaction reporting.
2023-05-24 English
Trading Update
Earnings Release Classification · 99% confidence The document begins with 'RNS Number' and is clearly distributed via RNS, the news service of the London Stock Exchange, which is approved by the FCA as a Primary Information Provider. The content is a 'Trading update' providing unaudited financial performance commentary for the period ending 30 June 2023, including a revision of the underlying operating profit guidance. This type of announcement, which provides key financial highlights and operational updates outside of a full quarterly or annual report, strongly aligns with an Earnings Release (ER). Although it mentions the ongoing M&A discussions, the primary purpose is the trading update/profit forecast revision. Since it is a formal regulatory announcement distributed via RNS, and it contains earnings-related information, ER is the most specific fit, although RNS is a possible fallback. Given the content is a trading update with revised profit guidance, ER is superior to RNS. FY 2023
2023-05-22 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.